Atrys Health (XMAD:ATRY) Growth Rank: 6 (As of Jul. 27, 2026) — 14% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ATRY Atrys Health SA XMAD:ATRY
62 GF Score
Price €2.48
GF Value €3.17
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Growth Rank?

Atrys Health XMAD:ATRY +1.22% 62 Growth Rank is 6 as of Jul. 27, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates XMAD:ATRY with a GF Score™ of 62/100 and a GF Value™ of €3.17 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Atrys Health has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

XMAD:ATRY vs VRTX, REGN, RVMD: Growth Rank Comparison

For the Biotechnology subindustry, Atrys Health's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrys Health Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's Growth Rank distribution charts can be found below:

* The bar in red indicates where Atrys Health's Growth Rank falls into.


XMAD:ATRY
62GF Score
Atrys Health SA XMAD:ATRY
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Atrys Health (XMAD:ATRY) has a Growth Rank of 6 as of Jul. 27, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Atrys Health and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Atrys Health's Growth Rank has ranged from 4.00 to 10.00.
Is Atrys Health's Growth Rank too high?
Atrys Health's current Growth Rank of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Atrys Health has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Growth Rank compare to VRTX and REGN?
Atrys Health's Growth Rank of 6 can be compared against companies in the Biotechnology industry. Historically, Atrys Health's own Growth Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Atrys Health and its competitors. Atrys Health's current Growth Rank is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.17, compared to a current price of €2.48 — trading 21.8% below its estimated fair value. The current Growth Rank is 6, which is 14% below median its 10-year median of 7.00. Atrys Health's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Growth Rank is 6 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.48 is trading 21.8% below its estimated GF Value™ of €3.17. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Growth Rank: 6 (14% below median its 10-year median of 7.00)
  • GF Value™: €3.17 vs. price of €2.48 (21.8% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
62GF Score

Get the complete analysis for XMAD:ATRY

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price
€3.17
GF Value